Phase 1 Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials
22 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 22 trials
Recruiting
Phase 1
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Phase 1
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)Soft Tissue Sarcoma (STS)+4 more
Novartis Pharmaceuticals66 enrolled1 locationNCT07630961
Recruiting
Phase 1
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)Metastatic DiseaseUnresectable Locally Advanced
Beijing Biotech42 enrolled1 locationNCT07627711
Recruiting
Phase 1
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 1Phase 2
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
Pancreatic Ductal Adenocarcinoma (PDAC)
Shenzhen Majory Biotechnology Co., Ltd.45 enrolled4 locationsNCT07235202
Recruiting
Phase 1
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Hepatocellular Carcinoma (HCC)Gastric Cancer (GC)+1 more
Shenzhen Xinhe Biomedical48 enrolled2 locationsNCT07594964
Recruiting
Phase 1Phase 2
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
Locally advanced and metastatic pancreatic cancerPancreatic Ductal Adenocarcinoma (PDAC)
West China Hospital55 enrolled1 locationNCT07595172
Recruiting
Phase 1Phase 2
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.754 enrolled21 locationsNCT05379985
Recruiting
Phase 1Phase 2
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Pancreatic CancerGastric CancerNon-small Cell Lung Cancer (NSCLC)+2 more
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
Phase 1Phase 2
The KN510713 Study in Combination With mFOLFIRINOX
Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
New Cancer Cure-Bio Co.,Ltd.30 enrolled1 locationNCT07114861
Recruiting
Phase 1
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
University of California, San Diego36 enrolled1 locationNCT06639724
Recruiting
Phase 1Phase 2
Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech42 enrolled1 locationNCT07480928
Recruiting
Phase 1
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Colorectal, CancerEsophageal CancerGastric Cancer+6 more
Sutro Biopharma, Inc.200 enrolled6 locationsNCT07227168
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Phase 1
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
Pancreatic Ductal Adenocarcinoma (PDAC)
University of Colorado, Denver10 enrolled1 locationNCT07030283
Recruiting
Phase 1Phase 2
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521
Recruiting
Phase 1Phase 2
HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)
West China Hospital20 enrolled1 locationNCT06773130